EGFR and neoplasm: Compared with visible light, the use of cetuximab-IRDye800CW enabled a more extensive resection of tumor tissue.20 A recent early phase 1 clinical trial (NCT02901925, ClinicalTtrials.gov) tested the ABY-029 affibody targeting EGFR, but the results have not yet been published.